Contribution of the Idylla TM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations.

Epidermal growth factor receptor (EGFR) genotyping, a critical examen for the treatment decisions of patients with non-small cell lung cancer (NSCLC), is commonly assayed by next-generation sequencing (NGS), but this global approach takes time. To determine whether rapid EGFR genotyping tests by the Idylla TM system guides earlier therapy decisions, EGFR mutations were assayed by both the Idylla TM system and NGS in 223 patients with NSCLC in a bicentric prospective study. Idylla TM demonstrated agreement with the NGS method in 187/194 cases (96.4%) and recovered 20 of the 26 (77%) EGFR mutations detected using NGS. Regarding the seven missed EGFR mutations, five were not detected by the Idylla TM system, one was assayed in a sample with insufficient tumoral cells, and the last was in a sample not validated by the Idylla TM system (a bone metastasis). Idylla TM did not detect any false positives. The average time between EGFR genotyping results from Idylla TM and the NGS method was 9.2 ± 2.2 working days (wd) (12.6 ± 4.0 calendar days (cd)). Subsequently, based on the Idylla TM method, the timeframe from tumor sampling to the initiation of EGFR-TKI was 7.7 ± 1.2 wd (11.4 ± 3.1 cd), while it was 20.3 ± 6.7 wd (27.2 ± 8.3 cd) with the NGS method ( p < 0.001). We thus demonstrated here that the Idylla TM system contributes to improving the therapeutic care of patients with NSCLC by the early screening of EGFR mutations.